The study, led by Barbara Bendlin, PhD, and Federico Rey, PhD, examined blood levels of imidazole propionate (ImP), a chemical produced by gut bacteria, and involved nearly 1,200 volunteer participants with the Wisconsin Alzheimer’s Disease Research Center (ADRC) and Wisconsin Registry for Alzheimer’s Prevention (WRAP) who showed no signs of cognitive impairment.